Francisco Delgado, MD
Infectious Disease · Carmel, INNPI 1619939055
Payments from drug & device makers
Across 120 payments — averaging $9187.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$842K
- Eli Lilly$241K
- Karyopharm Therapeutics Inc.$17K
- AbbVie$716
- La Jolla Pharmaceutical Company$549
- Merck$214
- plus $1K from 20 others
Across 3 payments — averaging $17,440 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$52K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 19 | $841,943 |
| Eli Lilly | 8 | $241,424 |
| Karyopharm Therapeutics Inc. | 7 | $16,550 |
| AbbVie(2 entities) | 15 | $716 |
| La Jolla Pharmaceutical Company | 5 | $549 |
| Merck | 16 | $214 |
| Actelion Pharmaceuticals US, Inc. | 7 | $199 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $147 |
| Baxter Healthcare | 4 | $115 |
| Janssen Products, LP | 1 | $102 |
| Johnson & Johnson | 6 | $79 |
| Grifols USA, LLC | 3 | $76 |
| Insmed, Inc. | 3 | $60 |
| Viiv Healthcare Company | 4 | $59 |
| Mayne Pharma Commercial LLC | 3 | $54 |
| Theratechnologies Inc. | 2 | $30 |
| Melinta Therapeutics, LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| GSK | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
| Smith+Nephew | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $15 |
| Amgen | 1 | $14 |
| Gilead | 1 | $13 |
How this compares
$1,102,504 in reported general payments places this provider in the 95th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Carmel
- Markian BochanCarmel$75K
- Tracey IkerdCarmel$39K
- Joshua BergCarmel$1K
- Chad TewellCarmel$1K
- Hassan ElmalikCarmel$1K
- Samir GuptaIndianapolis$1.5M
- Aaron ErmelIndianapolis$1.2M
- Darron BrownIndianapolis$822K
- Timothy FransonZionsville$303K
- Patrick MilliganIndianapolis$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.